Nanobiotix SA ADR NBTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NBTX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $5.81
- Day Range
- $5.71–5.83
- 52-Week Range
- $1.75–11.00
- Bid/Ask
- $5.70 / $6.00
- Market Cap
- $269.01 Mil
- Volume/Avg
- 470 / 38,074
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 102
- Website
- https://www.nanobiotix.com
Comparables
Valuation
|
Metric
|
NBTX
|
IMU
|
SGEN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.20 | 16.92 |
Price/Sales | 6.60 | — | 18.61 |
Price/Cash Flow | — | — | — |
Price/Earnings
NBTX
IMU
SGEN
Financial Strength
|
Metric
|
NBTX
|
IMU
|
SGEN
|
|---|---|---|---|
Quick Ratio | 0.63 | 5.46 | 1.96 |
Current Ratio | 0.67 | 5.73 | 2.67 |
Interest Coverage | −7.58 | — | — |
Quick Ratio
NBTX
IMU
SGEN
Profitability
|
Metric
|
NBTX
|
IMU
|
SGEN
|
|---|---|---|---|
Return on Assets (Normalized) | −52.73% | −41.83% | −13.05% |
Return on Equity (Normalized) | — | −45.23% | −17.35% |
Return on Invested Capital (Normalized) | −116.05% | −47.05% | −16.86% |
Return on Assets
NBTX
IMU
SGEN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lccwhxvgr | Ymzq | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nfdhnzfg | Sjwry | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wnyzxmd | Jbpfj | $98.3 Bil | |
MRNA
| Moderna Inc | Wskccxfw | Qdnd | $42.7 Bil | |
ARGX
| argenx SE ADR | Xvcxljc | Yphs | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Rlbxsgw | Dgt | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pvhysfsf | Kswgp | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mxblzttg | Jnmndr | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hjksqjrrs | Kyblcs | $12.7 Bil | |
INCY
| Incyte Corp | Ltbcyhfs | Hhhxkj | $11.8 Bil |